Clik here to view.
ReproCELL Announced: A Joint Development with the National Cancer Center
YOKOHAMA, Japan ReproCELL, Inc. (JASDAQ:4978): “ReproHP Medium,” a highly functional culture fluid for human primary liver cells developed in conjunction with the National Cancer Center, is set to...
View ArticleClik here to view.
Clik here to view.
Dentsu Announces Its Corporate Venture Capital Fund
TOKYO Dentsu Inc. (TOKYO: 4324; ISIN: JP3551520004; President & CEO: Tadashi Ishii; Head Office: Tokyo; Capital: 74,609.81 million yen) announced today that Dentsu Ventures Global Fund I...
View ArticleClik here to view.
Takeda Provides Further Information about its New Business Venture with Teva
OSAKA, Japan & Jerusalem Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) and Takeda Pharmaceutical Company Limited (TSE: 4502) today made the below follow-up announcement regarding the...
View ArticleClik here to view.
日本における武田薬品とテバ社による合弁会社の追加情報の公表について
大阪 & イスラエル・エルサレム （ビジネスワイヤ） — 武田薬品工業株式会社（本社：大阪市中央区、以下「武田薬品」）とTeva Pharmaceutical Industries Ltd. （本社：イスラエル...
View ArticleClik here to view.
Takeda Provides Further Information about Its New Business Venture with Teva
OSAKA, Japan & JERUSALEM Takeda Pharmaceutical Company Limited (TOKYO: 4502) and Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) (TASE: TEVA) today made the below follow-up announcement...
View ArticleClik here to view.
INSERTING and REPLACING Takeda Provides Further Information about its New...
OSAKA, Japan & Jerusalem Insert after 1st sentence in last bullet of release: The new business venture will be instantly accretive to Teva’s non GAAP EPS in 2016 and beyond. The corrected...
View ArticleClik here to view.
CORRECTING and REPLACING Takeda Provides Further Information about Its New...
OSAKA, Japan & JERUSALEM Insert after fifth paragraph, first sentence of release: The new business venture will be instantly accretive to Teva’s non GAAP EPS in 2016 and beyond. This Smart News...
View ArticleClik here to view.
訂正・差し替え 日本における武田薬品とテバ社による合弁会社の追加情報の公表について
大阪 & イスラエル・エルサレム （ビジネスワイヤ） — 武田薬品工業株式会社（本社：大阪市中央区、以下「武田薬品」）とTeva Pharmaceutical Industries Ltd. （本社：イスラエル...
View ArticleClik here to view.
武田就与Teva建立新企业事宜披露更多信息
日本大阪和与耶路撒冷 (美国商业资讯)–武田药品工业株式会社(Takeda Pharmaceutical Company Limited)(TOKYO: 4502)与Teva Pharmaceutical Industries Ltd. (NYSE: TEVA)(TASE:...
View ArticleClik here to view.
Dr. Reddy’s Announces the Relaunch of Esomeprazole Magnesium Delayed-Release...
HYDERABAD, India Dr. Reddy’s today announced the re-launch of its Esomeprazole Magnesium Delayed-Release Capsules, a therapeutic equivalent generic version of Nexium® (esomeprazole magnesium)...
View ArticleClik here to view.
Clik here to view.
新发表于《外科年报》的长期有利结果显示GORE BIO-A组织加固材料可有效修复复杂型腹部疝
亚利桑那州弗拉格斯塔夫 (美国商业资讯)–W. L. Gore & Associates, Inc. (Gore)今天发布了一项长期、前瞻性、多中心研究的最终结果，该研究评估生物合成网片GORE® BIO-A® 组织加固材料用于修复伤口污染患者的复杂型腹部疝(CVH)。该研究的主导研究者是克利夫兰诊所的Michael Rosen, MD，研究结果已被接受用于在《外科年报》发表。...
View ArticleClik here to view.
Phosphagenics Initiates Arbitration against Mylan
MELBOURNE, Australia Australian biotechnology company, Phosphagenics Limited (ASX:POH; OTCQX:PPGNY), announced today that it has commenced legal action against Mylan Laboratories Limited (Mylan), a...
View ArticleClik here to view.
Sanofi Genzyme Announces Recipients of Patient Advocacy Leadership (PAL) Awards
CAMBRIDGE, Mass. Sanofi Genzyme, the specialty care global business unit of Sanofi, today announced the recipients of the fifth annual Patient Advocacy Leadership (PAL) awards. The global grant...
View ArticleClik here to view.
Vyome Biosciences Announces FDA Acceptance of Investigational New Drug...
NEW DELHI Vyome Biosciences, a dermatology focused innovative bio-pharmaceutical company, pioneering the development of next generation antibiotics and antifungal products that target antimicrobial...
View ArticleClik here to view.
Bioventusが台湾で変形性関節症患者向けにデュロレーンを発売
蘭ホーフトドルプ （ビジネスワイヤ） — オーソバイオロジクス・ソリューションのリーダー企業のBioventusは本日、デュロレーンの発売を通じて台湾の患者ケア市場に参入したと発表しました。デュロレーンは変形性関節症（OA）治療のための関節内単回注射液で、NASHA®と呼ばれる技術プロセスを基盤としています。天然の物質を使用して安全で実証済みのNASHA®により、安定ヒアルロン酸を生成します。...
View ArticleClik here to view.
武田收购美国生物制剂制造设施
日本大阪 (美国商业资讯) –武田药品工业株式会社(TOKYO:4502) （“武田”）今天宣布收购Baxalta US Inc (NYSE:BXLT)位于明尼苏达州布鲁克林帕克的一处生物制剂制造设施。武田计划将此设施主要用于制造Entyvio® (vedolizumab)和其他生物制剂产品，以实现公司全球效率最大化，并进一步提升该产品的供应链灵活性。 武田全球制造及供应官Thomas...
View ArticleClik here to view.
Johnson & Johnson Innovation and Janssen Pharmaceuticals, Inc. Announce...
NEW BRUNSWICK, N.J. Johnson & Johnson Innovation and Janssen Pharmaceuticals, Inc. today announced an exclusive license agreement with Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CTTQ), a...
View ArticleClik here to view.
BioMarker Strategies Announces Issuance of Key Patents in the United States,...
ROCKVILLE, Md. BioMarker Strategies, LLC, today announced that patents covering its core technology have been granted in the United States, Europe, Australia and Hong Kong. “We developed the...
View Article